Harmanjit Singh

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 13

Top Topics

Placebo Controlled

Cardiovascular Risk Factors

Top Venues

Expert review of clinical pharmacology

Expert review of neurotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid
Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert review of clinical pharmacology (2023)
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid
Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert review of clinical pharmacology 16 (1) (2023)
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid
Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert review of clinical pharmacology 16 (1) (2023)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology 16 (1) (2022)
Harmanjit Singh, Dinesh Joshi, Seerat Narula, Mandeep Singla, Ravi Rohilla, Jagjit Singh
Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns. Expert review of clinical pharmacology 15 (2) (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert review of clinical pharmacology 16 (1) (2022)
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh, Farideh Javid
Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert review of clinical pharmacology (2022)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar, Ashish Kumar Kakkar
Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer? Current evidence and future directions. Expert review of clinical pharmacology (2022)
Harmanjit Singh, Prerna Chauhan, Jasbir Singh, null Saurabh, C S Gautam, Ashish Kumar Kakkar
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? Expert review of clinical pharmacology 14 (3) (2021)
Prerna Chauhan, Gurjit Kaur, Rajendra Prasad, Harmanjit Singh
Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert review of neurotherapeutics (2021)
Shashank Shekhar Gautam, C S Gautam, Vivek Kumar Garg, Harmanjit Singh
Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. Expert review of clinical pharmacology 13 (11) (2020)
Prerna Chauhan, Ashish Kumar Kakkar, Harmanjit Singh, C S Gautam
Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. Expert review of neurotherapeutics 21 (1) (2020)